MA44110B1 - Polythérapie - Google Patents
PolythérapieInfo
- Publication number
- MA44110B1 MA44110B1 MA44110A MA44110A MA44110B1 MA 44110 B1 MA44110 B1 MA 44110B1 MA 44110 A MA44110 A MA 44110A MA 44110 A MA44110 A MA 44110A MA 44110 B1 MA44110 B1 MA 44110B1
- Authority
- MA
- Morocco
- Prior art keywords
- cancer
- alaninyl
- benzoxy
- combination therapy
- phenyl
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- NHTKGYOMICWFQZ-KKQYNPQSSA-N benzyl (2s)-2-[[[(2r,3r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4,4-difluoro-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Chemical compound N1([C@@H]2O[C@@H]([C@H](C2(F)F)O)COP(=O)(N[C@@H](C)C(=O)OCC=2C=CC=CC=2)OC=2C=CC=CC=2)C=CC(N)=NC1=O NHTKGYOMICWFQZ-KKQYNPQSSA-N 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 210000000013 bile duct Anatomy 0.000 abstract 1
- 208000026900 bile duct neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 201000007487 gallbladder carcinoma Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 abstract 1
- 229950005566 picoplatin Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne une association de gemcitabine- [phényl-benzoxy-l-alaninyl)]-phosphate (nom chimique: 2 '-désoxy -2 ', 2 '-difluoro-d-cytidine -5 '-o- [phényl (benzoxy-l-alaninyl) ] phosphate) (nuc -1031) et un agent anticancéreux à base de platine choisi parmi le cisplatine, le picoplatine, le lipoplatine et le triplatine. Les combinaisons sont utiles dans le traitement du cancer et en particulier le cancer de la vésicule et des voies biliaires et le cancer de la vessie.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/054158 WO2017109444A1 (fr) | 2015-12-23 | 2015-12-23 | Traitement combiné |
| EP16820005.3A EP3393478B1 (fr) | 2015-12-23 | 2016-12-21 | Polythérapie |
| PCT/GB2016/054018 WO2017109486A1 (fr) | 2015-12-23 | 2016-12-21 | Polythérapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44110A MA44110A (fr) | 2018-10-31 |
| MA44110B1 true MA44110B1 (fr) | 2020-03-31 |
Family
ID=55069010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44110A MA44110B1 (fr) | 2015-12-23 | 2016-12-21 | Polythérapie |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190381084A1 (fr) |
| KR (1) | KR102566461B1 (fr) |
| AU (1) | AU2015418015B2 (fr) |
| CA (1) | CA3008769A1 (fr) |
| MA (1) | MA44110B1 (fr) |
| WO (1) | WO2017109444A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201503750YA (en) | 2012-11-16 | 2015-06-29 | Univ Cardiff | Process for preparing nucleoside prodrugs |
| HRP20230584T1 (hr) | 2014-06-25 | 2023-09-15 | NuCana plc | Prolijekovi gemcitabina |
| JP6855248B2 (ja) | 2014-06-25 | 2021-04-07 | ヌカナ ピーエルシー | ゲムシタビン−プロドラッグを含む製剤 |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| PH12018500691B1 (en) | 2015-10-05 | 2022-08-10 | NuCana plc | Combination therapy |
| HRP20211812T1 (hr) | 2015-12-11 | 2022-03-04 | NuCana plc | Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| EP3508205B1 (fr) | 2016-08-31 | 2022-05-18 | FUJIFILM Corporation | Agent antitumoral, activateur d'effet antitumoral et kit anti-tumoral |
| GB201713914D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Combination therapy |
| US20240115591A1 (en) * | 2020-11-03 | 2024-04-11 | Cornerstone Pharmaceuticals, Inc. | Therapeutic methods and compositions for treating biliary tract cancer using devimistat |
| EP4704902A1 (fr) * | 2023-05-05 | 2026-03-11 | Purdue Research Foundation | Polythérapie pour le traitement du cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| EP3415149A1 (fr) * | 2015-05-14 | 2018-12-19 | NuCana plc | Traitements du cancer |
-
2015
- 2015-12-23 WO PCT/GB2015/054158 patent/WO2017109444A1/fr not_active Ceased
- 2015-12-23 US US16/065,476 patent/US20190381084A1/en not_active Abandoned
- 2015-12-23 CA CA3008769A patent/CA3008769A1/fr active Pending
- 2015-12-23 KR KR1020187020532A patent/KR102566461B1/ko active Active
- 2015-12-23 AU AU2015418015A patent/AU2015418015B2/en not_active Ceased
-
2016
- 2016-12-21 MA MA44110A patent/MA44110B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015418015A1 (en) | 2018-07-05 |
| KR102566461B1 (ko) | 2023-08-14 |
| US20190381084A1 (en) | 2019-12-19 |
| WO2017109444A1 (fr) | 2017-06-29 |
| AU2015418015B2 (en) | 2021-12-09 |
| KR20180096697A (ko) | 2018-08-29 |
| MA44110A (fr) | 2018-10-31 |
| CA3008769A1 (fr) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44110B1 (fr) | Polythérapie | |
| PH12018501339A1 (en) | Combination therapy | |
| PH12018500691B1 (en) | Combination therapy | |
| MX2025001810A (es) | Compuestos que participan en la union cooperativa y usos de los mismos | |
| WO2018022668A3 (fr) | Compositions neuromodulatrices et méthodes associées de traitement du cancer | |
| WO2016049024A3 (fr) | Administration, utilisation et applications thérapeutiques des systèmes crispr-cas et compositions permettant de modéliser la concurrence de multiples mutations cancéreuses in vivo | |
| EA200970891A1 (ru) | Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы | |
| CY1120536T1 (el) | Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου | |
| BR112012024442A2 (pt) | métodos de tratamento de câncer | |
| TW200716141A (en) | Compositions and methods for treatment for neoplasms | |
| BR112016013547A2 (pt) | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos | |
| MX379717B (es) | Composiciones inhibidoras del eflujo y métodos de tratamiento mediante el uso de las mismas. | |
| EA201892803A1 (ru) | Противоопухолевая терапия | |
| MX370662B (es) | Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer. | |
| BR112019011199A2 (pt) | método para tratar um indivíduo que tem um câncer de próstata e kits | |
| EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| WO2007124314A3 (fr) | Utilisation de transporteurs de cations organiques pour le diagnostic et le traitement du cancer | |
| WO2009032172A3 (fr) | Compositions de platine en tant que traitement pour des cancers liés à un transporteur de cations organiques | |
| IN2014DN04596A (fr) | ||
| PH12019501682A1 (en) | Rorgamma modulators and uses thereof | |
| Hardee et al. | In reply—Resistance Training and Cancer Survival | |
| Spry et al. | Resistance Training and Cancer Survival/In Reply | |
| CL2018000861A1 (es) | Terapia de combinación. |